Higher expression of calcineurin predicts poor prognosis in unique subtype of ovarian cancer

Xin, Bing; Ji, Kai-Qiang; Liu, Yi-Si; Zhao, Xiao-Dong

doi:10.1186/s13048-019-0550-0

Journal of Ovarian Research

Table 1 Nonparametric analysis of CN expression in relation to various clinical parameters

From: Higher expression of calcineurin predicts poor prognosis in unique subtype of ovarian cancer

Clinical parameters	CN expression
	Total type			Clear-cell carcinoma			Serous carcinoma			Papillary serous cystadenocarcinoma
	N	Mean ± SD	p-value	N	Mean ± SD	p-value	N	Mean ± SD	p-value	N	Mean ± SD	p-value
Age (years)
< 50	20	38.25 ± 35.81	0.14	9	51.11 ± 38.87	0.63	3	26.67 ± 25.17	0.38	8	28.13 ± 34.43	0.15
≧50	21	53.33 ± 30.39	0.14	8	60.00 ± 31.17	0.63	6	48.33 ± 35.50	0.38	7	50.00 ± 28.28	0.15
Pathological stage
I~II	22	31.00 ± 22.73	0.16	8	45.00 ± 21.86	0.10	4	18.00 ± 22.50	0.03*	10	25.00 ± 31.23	0.25
III~IV	18	60.28 ± 33.72	0.16	8	71.25 ± 22.48	0.10	5	58.00 ± 21.50	0.03*	5	45.00 ± 32.75	0.25
Tumor size (mm³)
< 395	20	35.25 ± 35.67	0.04*	5	36.00 ± 39.12	0.20	6	36.67 ± 28.30	0.35	9	33.89 ± 36.55	0.39
≧395	21	56.19 ± 28.72	0.04*	12	63.33 ± 30.85		3	50.00 ± 20.00	0.35	6	45.00 ± 27.39	0.39
LN metastasis
No	24	31.25 ± 31.53	0.26	10	46.00 ± 32.04	0.12	4	20.00 ± 24.50	0.11	10	25.00 ± 31.23	0.25
Yes	17	52.65 ± 36.23	0.26	7	68.57 ± 36.25	0.12	5	58.00 ± 29.50	0.11	5	45.00 ± 32.75	0.25
Distant metastasis
No	40	40.13 ± 34.02	0.89	16	40.25 ± 35.57	0.68	9	41.11 ± 32.58	─	15	38.33 ± 32.61	─
Yes	1	40 ± 0	0.89	1	60 ± 0	0.68	0	─	─	0	─	─
Ascites
No	21	45.24 ± 33.11	0.88	10	52.00 ± 34.90	0.66	6	36.67 ± 38.30	0.55	5	42.00 ± 25.88	0.68
Yes	20	46.75 ± 34.95	0.88	7	60.00 ± 36.52	0.66	3	50.00 ± 20.00	0.55	10	36.50 ± 36.67	0.68
Chemotherapeutic response
No	2	50.00 ± 56.57	0.91	1	90.00 ± 0	0.32	0	─	─	1	10 ± 0	0.62
Yes	32	47.34 ± 33.41	0.91	13	53.85 ± 35.72	0.32	7	50.00 ± 31.09		12	38.75 ± 33.04	0.62
Chemotherapeutic resistance
No	18	35.83 ± 30.01	0.49	5	46.00 ± 28.81	0.81	2	15.00 ± 21.21	─	11	35.00 ± 31.86	0.49
Yes	8	45.00 ± 33.81	0.49	4	42.50 ± 35.00	0.81	0	─		4	47.50 ± 37.75	0.49
CA125 (U/ml)
< 324	22	48.86 ± 34.22	0.66	11	51.82 ± 37.10	0.04*	3	50.00 ± 20.00	0.55	8	44.38 ± 37.36	0.61
≧324	18	44.44 ± 33.47	0.66	5	72.00 ± 21.68	0.04*	6	36.67 ± 38.30	0.55	7	31.43 ± 27.34	0.61
CA19–9 (U/ml)
< 21.55	21	50.00 ± 37.68	0.69	8	65.00 ± 34.23	0.90	6	41.67 ± 39.71	1.00	7	40.00 ± 39.58	0.71
≧21.55	17	44.71 ± 28.75	0.69	7	50.00 ± 36.52	0.90	3	40.00 ± 17.32	1.00	7	41.43 ± 26.73	0.71
CA72–4 (U/ml)
< 7.89	19	47.89 ± 37.94	0.98	8	58.75 ± 39.80	0.83	3	23.33 ± 40.42	0.38	8	46.25 ± 35.43	0.39
≧7.89	21	45.95 ± 29.90	0.98	8	57.50 ± 29.16	0.83	6	50.00 ± 27.57	0.38	7	29.29 ± 28.93	0.39
AFP (ng/mL)
< 2.9	22	28.86 ± 20.08	0.24	7	57.14 ± 27.52	0.63	3	40.00 ± 36.06	0.91	12	6.67 ± 5.77	0.03*
≧2.9	18	44.44 ± 28.08	0.24	9	58.88 ± 39.51	0.63	6	41.67 ± 34.30	0.91	3	46.25 ± 31.70	0.03*
CEA (ng/mL)
< 1.48	17	48.82 ± 27.36	0.83	8	45.00 ± 34.23	0.14	4	47.50 ± 320.62	0.56	5	56.00 ± 23.02	0.15
≧1.48	22	47.05 ± 38.07	0.83	8	71.25 ± 29.49	0.14	5	36.00 ± 41.59	0.56	9	31.67 ± 35.36	0.15

Statistical analysis using Mann-Whitney U test; LN, lymph node; CA125, cancer antigen 125; CA19–9, cancer antigen 19–9; CA72–4, cancer antigen 72–4; AFP, alpha-fetoprotein; CEA, carcinoembryonic antigen; *p < 0.05

Back to article page

ISSN: 1757-2215

Contact us

General enquiries: journalsubmissions@springernature.com